Combination Study of Deferasirox and Erythropoietin in Patients With Low- and Int-1-risk Myelodysplastic Syndrome.

Inclusion Criteria

• •Patients who had low- and Int-1-risk myelodysplastic syndrome
• •Documented diagnosis of the following:
• •Myelodysplastic syndrome that lasted ≥ 3 months and \< 3 years Disease must not have been secondary to treatment with radiotherapy, chemotherapy, and/or immunotherapy for malignant or autoimmune diseases
• •A hemoglobin \< 10 g/dL and ≥ 8 g/dL
• •History of transfusions \< 10 RBC units and must not have been RBC transfusion dependent
• •300 ng/mL \< serum ferritin \< 1,500 ng/mL (Values within 10% difference above 1500 ng/ml or 10% difference below 300 ng/ml could have been accepted at the investigator's discretion.
• •Endogenous erythropoietin levels \< 500 units/L
• •Serum creatinine ≤ 1.5 times upper limit of normal (ULN)
• •Creatinine clearance above the concentration limit in locally approved prescribing information (PI). Patients with creatinine clearance between 40 and less than 60 mL/min, who did not present with additional risk factors that might impair renal function, were eligible at the discretion of the investigator